Lei Y, Zhao X, Hong M, Liu W, Sun Q, Qian S
Zhonghua Xue Ye Xue Za Zhi. 2025; 45(12):1129-1133.
PMID: 39765355
PMC: 11886698.
DOI: 10.3760/cma.j.cn121090-20240615-00224.
Gupta S, Jose N, Tafuto B
Princ Pract Clin Res. 2024; 10(2):47-59.
PMID: 39640233
PMC: 11618817.
DOI: 10.21801/ppcrj.2024.102.7.
Kouidri K, Acker F, Toenges R, Pfaff S, Lindner S, Riemann J
Ann Hematol. 2024; 103(12):5387-5393.
PMID: 39589497
PMC: 11695448.
DOI: 10.1007/s00277-024-06106-y.
Lin W, Chao C, Lin C, Hsu Y, Hsiao S, Weng T
Mol Clin Oncol. 2024; 21(6):93.
PMID: 39478693
PMC: 11523226.
DOI: 10.3892/mco.2024.2791.
Short N, Daver N, DiNardo C, Kadia T, Nasr L, Macaron W
J Clin Oncol. 2024; 42(13):1499-1508.
PMID: 38277619
PMC: 11095865.
DOI: 10.1200/JCO.23.01911.
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.
Short N, Nguyen D, Ravandi F
Blood Cancer J. 2023; 13(1):142.
PMID: 37696819
PMC: 10495326.
DOI: 10.1038/s41408-023-00911-w.
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches.
Tecik M, Adan A
Onco Targets Ther. 2022; 15:1449-1478.
PMID: 36474506
PMC: 9719701.
DOI: 10.2147/OTT.S384293.
Evolution of Graves' Disease during Immune Reconstitution following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation in a Boy Carrying Germline and Variants.
Ip P, Fang L, Shen Y, Tung K, Lai M, Juan L
Int J Mol Sci. 2022; 23(16).
PMID: 36012751
PMC: 9409095.
DOI: 10.3390/ijms23169494.
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies.
Griffioen M, De Leeuw D, Janssen J, Smit L
Cancers (Basel). 2022; 14(14).
PMID: 35884517
PMC: 9318140.
DOI: 10.3390/cancers14143456.
Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios.
Qiu K, Liao X, Liu Y, Huang K, Li Y, Fang J
Nat Commun. 2022; 13(1):3679.
PMID: 35760968
PMC: 9237020.
DOI: 10.1038/s41467-022-31489-9.
Resistance to targeted therapies: delving into FLT3 and IDH.
Desikan S, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F
Blood Cancer J. 2022; 12(6):91.
PMID: 35680852
PMC: 9184476.
DOI: 10.1038/s41408-022-00687-5.
Target Therapy for Extramedullary Relapse of -ITD Acute Myeloid Leukemia: Emerging Data from the Field.
Duminuco A, Maugeri C, Parisi M, Mauro E, Fiumara P, Randazzo V
Cancers (Basel). 2022; 14(9).
PMID: 35565314
PMC: 9105351.
DOI: 10.3390/cancers14092186.
A novel approach for relapsed/refractory FLT3 acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.
Li K, Wu H, Pan W, Guo M, Qiu D, He Y
Mol Cancer. 2022; 21(1):66.
PMID: 35246156
PMC: 8896098.
DOI: 10.1186/s12943-022-01541-9.
A review of FLT3 inhibitors in acute myeloid leukemia.
Zhao J, Agarwal S, Ahmad H, Amin K, Bewersdorf J, Zeidan A
Blood Rev. 2021; 52:100905.
PMID: 34774343
PMC: 9846716.
DOI: 10.1016/j.blre.2021.100905.
CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.
Tariq M, Furqan M, Parveen H, Ullah R, Muddassar M, Saleem R
Br J Cancer. 2021; 125(7):966-974.
PMID: 34446858
PMC: 8476516.
DOI: 10.1038/s41416-021-01527-2.
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
Daver N, Venugopal S, Ravandi F
Blood Cancer J. 2021; 11(5):104.
PMID: 34045454
PMC: 8159924.
DOI: 10.1038/s41408-021-00495-3.
Novel Approaches to Target Mutant FLT3 Leukaemia.
Muller J, Schmidt-Arras D
Cancers (Basel). 2020; 12(10).
PMID: 33003568
PMC: 7600363.
DOI: 10.3390/cancers12102806.
Potential targeting of FLT3 acute myeloid leukemia.
Ambinder A, Levis M
Haematologica. 2020; 106(3):671-681.
PMID: 32703795
PMC: 7927884.
DOI: 10.3324/haematol.2019.240754.
Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress.
Hu X, Cai J, Zhu J, Lang W, Zhong J, Zhong H
Cancer Cell Int. 2020; 20:250.
PMID: 32565734
PMC: 7298957.
DOI: 10.1186/s12935-020-01341-5.
Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy.
Kattner A, Holler E, Herr W, Reichle A, Wolff D, Heudobler D
Front Oncol. 2020; 10:443.
PMID: 32391254
PMC: 7190808.
DOI: 10.3389/fonc.2020.00443.